Pfizer Considers Relocating Overseas Manufacturing to U.S. Facilities

CEO Albert Bourla outlines contingency plans as Trump administration threatens 25% tariffs on imported pharmaceuticals.

Pfizer CEO Albert Bourla stated that the company may shift overseas drug production to its U.S. facilities to mitigate the impact of potential tariffs.
The Trump administration has proposed a 25% tariff on imported pharmaceuticals as part of broader trade policies targeting Mexico, Canada, China, and the EU.
Pfizer currently operates 13 manufacturing sites and two distribution centers in the U.S., which Bourla described as capable of absorbing increased production.
Bourla emphasized that while the company is prepared to adapt quickly, relocating manufacturing is logistically complex and may require government support or public-private partnerships.
Other pharmaceutical companies, including Eli Lilly, have announced significant U.S. investments following pressure from the administration to increase domestic production.